Knowles Corporation (KN)

Executive Summary / Key Takeaways

• Knowles has completed a five-year transformation from a consumer-exposed MEMS supplier to a pure-play industrial technology company, with the December 2024 sale of its Consumer MEMS Microphone business marking the final pivot toward medtech, defense, and electrification markets that command structurally higher margins and more durable demand.

• Precision Devices has emerged as the company's earnings engine, delivering 19.2% adjusted EBIT margins with a 35-40% drop-through rate on incremental revenue, while the specialty film capacitor ramp-up positions the segment to capture $50-65 million in new energy market revenue in 2026, representing a step-change in both growth and profitability.

• MedTech Specialty Audio provides a stable foundation of 38.7% adjusted EBIT margins and resilient hearing health demand that historically rebounds quickly from economic shocks, creating a defensive cash-generating asset that funds investment in higher-growth opportunities while reducing overall business volatility.

• The company is executing a margin expansion story with 140 basis points of gross margin improvement in 2025 to 44.5%, guided to expand another 50-75 basis points in 2026, driven by factory utilization gains, pricing power in defense markets, and the specialty film line ramp that will reach full production by Q2 2026.

• A fortress balance sheet with 0.4x net leverage and $129 million remaining buyback authorization provides substantial optionality, enabling Knowles to pursue synergistic acquisitions, fund capacity expansion for the energy order, and return capital to shareholders while maintaining financial flexibility through cyclical downturns.

Setting the Scene: From Consumer Commodity to Industrial Precision

Knowles Corporation, founded in 1946 and headquartered in Itasca, Illinois, spent most of its history as a diversified electronic components manufacturer before embarking on a deliberate five-year strategic transformation. The company systematically reduced investment in the volatile consumer electronics market while building scale in medtech, defense, industrial, and electrification applications. This journey culminated in two pivotal transactions: the November 2023 acquisition of Cornell Dubilier Electronics for $259.8 million, which added high-performance capacitor capabilities to the Precision Devices segment, and the December 2024 divestiture of its Consumer MEMS Microphone business to Syntiant Corp, which eliminated the last major exposure to consumer cyclicality.

The company now operates as a focused industrial technology pure-play through two reportable segments. Precision Devices designs and manufactures high-performance capacitors and RF solutions for applications where failure is not an option: implantable medical devices, electronic warfare systems, electric vehicle powertrains, and energy infrastructure. MedTech Specialty Audio produces balanced armature speakers and microphones for hearing health and specialty audio markets, where miniaturization, reliability, and power efficiency determine product viability. This bifurcated structure creates a unique investment profile: one segment drives growth through technological leadership in emerging markets, while the other provides stability through essential medical devices with aging demographic tailwinds.

Industry structure favors Knowles' positioning. Defense spending on electronic warfare is accelerating as global conflict drives demand for custom RF solutions with domestic manufacturing footprints. The medtech market benefits from increasing life expectancy and aging populations, with hearing health showing remarkable resilience through economic cycles. Electrification and energy transition create new demand for high-power capacitors that can handle extreme conditions. Industrial automation recovery, with distribution inventory levels normalizing after a prolonged destocking period, provides a cyclical tailwind. These trends converge on a common requirement: components that are not commodities but critical enablers of system performance, where engineering partnership and customization create pricing power and sticky customer relationships.

Technology, Products, and Strategic Differentiation

Precision Devices' competitive moat rests on its ability to customize high-performance capacitors at scale while maintaining world-class manufacturing quality. The specialty film capacitor line represents the most significant technology expansion in recent company history. These capacitors address accelerating power demand in applications ranging from defibrillators and radiotherapy equipment to downhole drilling, fracking, and military rail guns. The technology enables substantially higher voltage tolerance and reliability in harsh environments compared to standard multilayer ceramic capacitors, creating a 5-10% pricing premium and insulating the product from commodity competition.

The economic impact of this technology shift becomes clear when examining the production timeline. Management expects the specialty film line to contribute $50-65 million in revenue during 2026, with deliveries commencing in 2026 for a large energy order that required substantial customer prepayment in Q1 2025. This prepayment, amounting to $19.8 million, signals customer commitment and reduces Knowles' capital risk while validating market demand. The production ramp faces execution challenges—yields were lower than expected in early 2025—but management has established a new prototype line and expects linear improvement through Q2 2026, when full volume production will unlock gross margin benefits that have been suppressed by ramp-up costs.

Proximity manufacturing forms a second, underappreciated competitive advantage. Knowles builds products in the geographic region where they ship: U.S. production serves U.S. customers, Asian production serves Asian and European customers. This strategy, combined with sourcing materials near production facilities, limits direct tariff exposure to less than 5% of revenue and indirect exposure to less than 3% of cost of goods sold. When tariffs are incurred, management has successfully passed costs to customers without business loss, preserving margins while competitors with extended Asian supply chains face margin compression or customer pushback. This strategic alignment transforms trade policy from a risk factor into a potential tailwind, as industrial customers increasingly prioritize supply security over marginal cost savings.

MedTech Specialty Audio's technology differentiation centers on balanced armature speakers that deliver superior performance in miniaturized form factors. These devices enable hearing aid manufacturers to improve comfort, fit, and battery life while maintaining audio quality. The microsolutions group within MSA is leveraging this core technology into new medical applications, collecting non-recurring engineering fees that will ramp into higher volume production in 2027. This creates a pipeline of embedded growth options that require minimal incremental capital, as existing manufacturing capacity and R&D infrastructure support the expansion.

Financial Performance & Segment Dynamics: Evidence of Strategic Success

Precision Devices' financial trajectory validates the transformation thesis. Segment revenue grew 9.6% in 2025 to $328.9 million, with Q4 accelerating to 23% year-over-year growth. Adjusted EBIT margins expanded to 19.2% in 2025 from 16.7% in 2024, driven by a powerful combination of factors: increased factory capacity utilization in ceramic capacitor and RF filter businesses, product cost reductions, higher average pricing in defense and medtech markets, and lower precious metal costs. The segment's 35-40% drop-through rate on incremental revenue means that each additional dollar of sales generates $0.35-0.40 of EBIT, creating operating leverage that will become more pronounced as the specialty film line reaches scale.

The segment's bookings trend reinforces sustainability. PD achieved a book-to-bill ratio above 1.15 for three consecutive quarters through Q2 2025, with Q4 marking another quarter of healthy bookings above 1.0 despite strong shipments. Distribution channel inventories have normalized, indicating that revenue growth reflects end-market demand rather than inventory restocking. This suggests the 2025 growth is durable, not a temporary cyclical bounce, and positions the segment for continued expansion in 2026.

MedTech Specialty Audio provides a contrasting but complementary financial profile. Revenue grew 4.3% in 2025 to $264.3 million, at the high end of management's 2-4% target range. Adjusted EBIT margins remained robust at 38.7%, though down slightly from 40.4% in 2024 due to unfavorable product mix from lower-margin metal cans supplied to Syntiant as part of the CMM sale agreement. This headwind will diminish as the supply agreement matures, while core hearing health margins remain above 50%. The segment's stability generates consistent cash flow to fund PD's growth investments and provides a defensive anchor during economic uncertainty.

Consolidated results reflect the segment dynamics. Full-year 2025 revenue of $593 million grew 7% organically, exceeding the high end of the 4-6% target presented at the May 2025 Investor Day. Gross margin improved 140 basis points to 44.5%, while adjusted EBITDA grew 9% to $140 million. Cash from operations was $114 million, or 19.2% of revenues, despite $32.5 million in payments to settle CMM supplier obligations and the absence of $24.4 million in cash that CMM generated in 2024. Adjusted free cash flow increased to $114.4 million from $93.8 million in 2024, demonstrating the underlying cash generation strength of the continuing operations.

Capital allocation reflects management's confidence and strategic discipline. The company repurchased $65 million in shares during 2025, leaving $129 million in authorization as of December 31, 2025. Capital expenditures were 5.4% of revenue in 2025, elevated by investments in the specialty film line, but are expected to normalize to 4-5% in 2026. With a net leverage ratio of 0.4x based on trailing twelve months adjusted EBITDA and liquidity exceeding $340 million from cash plus unused revolver capacity, Knowles has substantial firepower for synergistic acquisitions while maintaining its investment-grade financial profile.

Outlook, Guidance, and Execution Risk

Management's 2026 guidance signals confidence in sustained above-historic growth. Q1 2026 revenue is projected at $143-153 million, representing 12% year-over-year growth at the midpoint, while EPS of $0.22-0.26 implies 33% growth. This acceleration suggests the transformation is gaining momentum rather than plateauing, with both segments contributing to the upside. The full-year outlook calls for organic growth at the high end of the 4-6% range, which management notes is above historical levels, indicating a structurally higher growth trajectory.

The specialty film ramp represents the critical execution variable for 2026. Management expects revenue of $50-65 million from this product category, including the large energy order, with production starting late in Q2 2026 and reaching full volume by quarter-end. Gross margin improvement will be weighted toward the back half of 2026, with the full benefit not realized until Q3 when production is fully ramped. This timeline creates a clear catalyst path: Q1 and Q2 will show steady progress, but Q3 should deliver a step-function improvement in both revenue and margins if execution holds. The risk is that yield issues or production delays could push benefits into 2027, compressing the 2026 earnings story.

End-market dynamics support the guidance framework. Defense demand remains robust across electronic warfare programs where Knowles is a sole-source supplier. Medtech continues its resilient growth pattern, with hearing health showing no signs of demand degradation. Industrial markets are expected to see strong shipments in the first half of 2026, with the back half flattening compared to 2025's strong second half but still delivering full-year growth. The energy order provides visibility into 2026, while new medical applications in the microsolutions group create a 2027 growth option that requires minimal near-term investment.

Management's commentary on tariffs and commodities reveals proactive risk management. Palladium costs have increased, but Knowles has pre-bought positions through the first half of 2026 at prices below current market rates, with monitoring for opportunities to extend hedges. This matters because it demonstrates operational sophistication in managing input costs that directly impact gross margins, a key variable for the 2026 expansion story.

Risks and Asymmetries

Customer concentration in MedTech Specialty Audio presents the most visible risk. The segment's top five customers accounted for 76% of revenue in 2025, with WS Audiology representing 24% of MSA and 11% of consolidated revenue. If a major customer were to insource production or shift to a competitor, the revenue impact would be material. However, the hearing health market's technology barriers and regulatory requirements create switching costs, while Knowles' superior performance in miniaturization and power efficiency makes substitution difficult. The risk is real but mitigated by product stickiness and the essential nature of hearing aids for an aging population.

Defense contract dependency creates compliance and concentration risk. A significant portion of PD revenue depends on U.S. government contracts that require adherence to complex procurement regulations. Failure to comply could result in suspension or debarment, while budget sequestration or shifts in defense priorities could reduce funding for electronic warfare programs. The mitigating factor is Knowles' sole-source position on several key programs and the strategic imperative driving defense electronics spending, making substitution unlikely even in budget-constrained environments.

Supply chain vulnerabilities remain despite the proximity manufacturing strategy. The company relies on highly specialized or sole-source suppliers for critical materials and components, particularly in the specialty film production ramp. Disruption at a single supplier could delay the 2026 revenue and margin catalyst. Management has addressed this by qualifying multiple suppliers where possible and maintaining higher safety stock, but the risk cannot be eliminated entirely.

Commodity price volatility, particularly in precious metals like palladium, could compress margins if hedging proves insufficient. While management has secured favorable pricing through mid-2026, sustained price increases beyond that period would eventually flow through to cost of goods sold. The 35-40% drop-through rate works in both directions, meaning cost inflation would disproportionately impact profitability if pricing power cannot keep pace.

The specialty film ramp itself represents an execution asymmetry. Successful ramp-up by Q2 2026 could drive margins toward the high end of the 50-75 basis point expansion target, potentially exceeding guidance if yields exceed expectations. Conversely, production delays or quality issues could push benefits into 2027, creating a disappointing 2026 earnings trajectory that would likely compress the valuation multiple. The customer prepayment reduces downside risk but does not eliminate execution risk entirely.

Valuation Context

Trading at $26.30 per share, Knowles carries a market capitalization of $2.25 billion and an enterprise value of $2.33 billion. The stock trades at 20.3x trailing EBITDA and 27.5x free cash flow, premiums to industrial component peers like Infineon (IFNNY) and Murata (MRAAY) but justified by the transformation story and margin expansion potential. The EV/Revenue multiple of 3.9x aligns closely with precision component peers, suggesting the market has not yet fully priced the earnings leverage from the specialty film ramp.

Balance sheet quality stands out in the peer group. Knowles' debt-to-equity ratio of 0.17 compares favorably to Infineon (0.42), Goertek (002241.SZ) (0.59), and AAC Technologies (AACAY) (0.43), while its current ratio of 2.75 exceeds all major competitors. This financial strength enables the company to self-fund the specialty film capacity expansion, pursue acquisitions without diluting shareholders, and sustain buybacks through cyclical downturns. The 0.4x net leverage ratio provides substantial debt capacity if needed for strategic opportunities.

Cash flow metrics reveal operational efficiency. The price-to-operating cash flow ratio of 19.7x is reasonable for a company generating 19.2% OCF margins, while the 27.5x free cash flow multiple reflects elevated capex for the specialty film line. As capex normalizes to 4-5% of revenue in 2026 and the specialty film contribution accelerates, free cash flow conversion should improve, potentially compressing the multiple. The absence of a dividend payout ratio indicates management is prioritizing growth investments and share repurchases over income distribution, appropriate for a company in a transformation phase.

Relative to historical trading patterns, the current valuation appears to price in moderate success on the specialty film ramp but not a best-case scenario. Peers with similar margin profiles and growth trajectories typically trade at 15-18x EBITDA, suggesting 20-30% upside if Knowles executes on its 2026 guidance and demonstrates the durability of its margin expansion. The key valuation driver will be Q3 2026 results, when the specialty film line reaches full production and the margin benefit becomes visible.

Conclusion

Knowles Corporation has completed a fundamental transformation from a commoditized consumer component supplier to a focused industrial technology company with durable competitive advantages in high-growth markets. The Precision Devices segment has emerged as a true earnings engine, combining 19.2% adjusted EBIT margins with a 35-40% drop-through rate and a clear catalyst in the specialty film capacitor ramp that should deliver $50-65 million in new revenue and significant margin expansion in 2026. MedTech Specialty Audio provides a stable foundation of 38.7% margins and resilient hearing health demand that reduces downside risk while generating cash to fund growth investments.

The investment thesis hinges on execution of the specialty film production ramp by Q2 2026 and realization of the associated margin benefits in the second half of the year. Management's guidance for 12% revenue growth and 33% EPS growth in Q1 2026, combined with full-year organic growth at the high end of 4-6%, suggests confidence that is supported by strong bookings trends and normalized distribution inventories. The company's fortress balance sheet, with 0.4x leverage and substantial buyback capacity, provides downside protection and optionality for value-creating M&A.

This story is attractive due to the convergence of multiple tailwinds: defense spending on electronic warfare, medtech demand from aging demographics, electrification infrastructure buildout, and industrial automation recovery. The primary risks involve execution on the specialty film ramp and customer concentration in the MSA segment. The next twelve months will determine whether Knowles can deliver on its margin expansion promise and cement its position as a premium industrial technology company worthy of a higher valuation multiple. Critical variables to monitor include specialty film yields, Q3 2026 margin progression, and any signs of share loss among the top MSA customers. If execution holds, the stock's current valuation offers meaningful upside as earnings power inflects higher.